亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma

无容量 医学 易普利姆玛 中止 内科学 不利影响 间皮瘤 外科 胃肠病学 肿瘤科 免疫疗法 癌症 病理
作者
D. Dumoulin,Li-Anne H Douma,M.M. Hofman,Vincent van der Noort,Robin Cornelissen,Cornedine J. de Gooijer,Jacobus A. Burgers,Joachim Aerts
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:187: 107440-107440
标识
DOI:10.1016/j.lungcan.2023.107440
摘要

ObjectivesNivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab improved the survival, however, 30.3% of the patients suffered from grade 3–4 treatment related adverse events (TRAE’s) and TRAE’s led to discontinuation in 23.0% of all patients. Here, we present the first real-world data of nivolumab plus ipilimumab in patients with malignant mesothelioma treated in two mesothelioma expert centers.MethodsClinical data of patients with mesothelioma treated with nivolumab and ipilimumab were prospectively collected. Clinical parameters were obtained every visit, CT scans were evaluated every 12 weeks and adverse events were assessed continuously during the treatment. Data on grade 2–5 TRAE’s and activity (overall response rate (ORR), duration of response (DOR), disease control rate (DCR), median progression-free survival (mPFS) and median overall survival (mOS) were reported.ResultsBetween January 2021 and August 2022, 184 patients were treated with nivolumab plus ipilimumab. The median follow-up was 12.1 months (95 %CI 11.1 – 13.1). Grade 3–4 TRAEs were seen in 27.7 % of the patients and 25.0 % discontinued immunotherapy treatment early because of TRAE’s. ORR was 21.7 % (95 % CI 15.7–27.7), median DOR was 5.7 months (IQR 3.2–8.7) and DCR at 12 weeks 56.0 % (95 % CI 48.8–63.2). The mPFS was 5.5 months (95 %CI 4.1–6.9), mOS was 14.1 months (95 % CI 11.1–18.2).ConclusionsNivolumab plus ipilimumab had an equal efficacy in a real-world comparable population but also a high risk of TRAE’s, leading to discontinuation of treatment in 25% of the patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lan发布了新的文献求助10
2秒前
3秒前
一杆长空完成签到,获得积分10
5秒前
热情的未来完成签到,获得积分20
11秒前
义气的蝴蝶完成签到,获得积分10
12秒前
13秒前
临水思长完成签到,获得积分10
14秒前
Lyuhng+1完成签到 ,获得积分10
15秒前
jyy应助薄红采纳,获得10
28秒前
29秒前
量子星尘发布了新的文献求助10
31秒前
kdjm688发布了新的文献求助10
36秒前
科研通AI2S应助cos采纳,获得10
39秒前
FashionBoy应助cos采纳,获得10
39秒前
多情的忆之完成签到,获得积分10
50秒前
pamper完成签到 ,获得积分10
50秒前
51秒前
57秒前
零度完成签到 ,获得积分10
1分钟前
kdjm688发布了新的文献求助10
1分钟前
超级微笑完成签到 ,获得积分10
1分钟前
1分钟前
领导范儿应助完美的流沙采纳,获得10
1分钟前
酷酷的枕头完成签到,获得积分10
1分钟前
刘明坤完成签到 ,获得积分10
1分钟前
SMULJL发布了新的文献求助10
1分钟前
带虾的烧麦完成签到,获得积分10
1分钟前
kdjm688发布了新的文献求助30
1分钟前
克姑美完成签到 ,获得积分10
1分钟前
CipherSage应助杜本内采纳,获得10
1分钟前
123完成签到,获得积分10
1分钟前
SMULJL完成签到,获得积分10
1分钟前
1分钟前
123发布了新的文献求助30
1分钟前
嗯哼哈哈完成签到 ,获得积分10
1分钟前
1分钟前
纯情的无色完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976608
求助须知:如何正确求助?哪些是违规求助? 3520700
关于积分的说明 11204542
捐赠科研通 3257350
什么是DOI,文献DOI怎么找? 1798716
邀请新用户注册赠送积分活动 877881
科研通“疑难数据库(出版商)”最低求助积分说明 806613